This trial is active, not recruiting.

Conditions stroke, atherosclerosis
Treatment magnetic resonance imaging (mri), multidetector computed tomography (mdct), ultrasonography (us), transcranial doppler (tcd)
Sponsor Maastricht University Medical Center
Start date September 2010
End date December 2016
Trial size 244 participants
Trial identifier NCT01208025, 09-2-082


The possibility of the identification of the risk of rupture of a carotid plaque will have tremendous impact in clinical decision making. Firstly, in symptomatic patients with a 30-69% stenosis, who are currently not operated upon according to the current guidelines, identification of the risk of rupture plaque could identify patients who have a high risk of recurrent stroke, and would benefit of carotid intervention, such as endarterectomy or stent placement. This could potentially prevent a substantial number of strokes. Secondly, in all symptomatic patients with a 70-99% stenosis carotid intervention should be considered, according to the guidelines. However, only one out of six patients with a 70-99% stenosis benefits from a carotid intervention. Identification of patients with a high risk of a recurrent stroke would reduce the number of unnecessary interventions substantially.

The main objective is to show whether imaging characteristics assessed at baseline can predict clinical events in patients with a 30-69 % symptomatic carotid stenosis.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Time perspective prospective
Patients with neurological symptoms due to ischemia in the carotid artery territory and with a carotid stenosis between 30% and 69% according to the European Carotid Surgery Trial (ECST) criteria.
magnetic resonance imaging (mri), multidetector computed tomography (mdct), ultrasonography (us), transcranial doppler (tcd)
3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)

Primary Outcomes

time frame: within 5 years of follow-up

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - neurological symptoms due to ischemia in the carotid artery territory as diagnosed by their neurologist based on anamneses, physical examination and brain imaging (CT or MRI) - carotid artery stenosis < 70% (upper cut-off value is based on the NASCET criteria, the lower cut-off value is an atherosclerotic plaque with a thickness of at least 2-3 mm, which corresponds to an ECST stenosis of 30% - written informed consent Exclusion Criteria: - patients with probable cardiac source of embolism (rhythm disorders, mitral valve stenosis, prolapse or calcification, mechanical cardiac valves, recent myocardial infarction, left ventricular thrombus, atrial myxoma, endocarditis, dilated cardiomyopathy, patent foramen ovale) or a clotting disorder - patients with evident other cause of neurological symptoms than carotid stenosis due to atherosclerotic disease (like demyelinating diseases, epilepsy, congenital brain disorders, aneurysms, fibromuscular dysplasia etc) - patients already scheduled for carotid endarterectomy or stenting. - severe co-morbidity, dementia or pregnancy - standard contra-indications for MRI - patients who have a documented allergy to MRI or CT contrast media - patients with renal clearance < 30 ml/minute are not eligible to undergo contrast-enhanced MRI - patients with renal clearance < 60 ml/minute are not eligible to undergo MDCT - patients who had a TIA or minor stroke more than 3 months before inclusion

Additional Information

Official title The Assessment of the Plaque at RISK by Non-invasive (Molecular) Imaging and Modelling (ParisK): Prospective Clinical Study for Diagnosis Efficacy for High Risk Plaque and Stroke.
Principal investigator Eline Kooi, PhD
Trial information was received from ClinicalTrials.gov and was last updated in September 2016.
Information provided to ClinicalTrials.gov by Maastricht University Medical Center.